Opportunities for Easing BTK Inhibitor Switches

Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.

EP: 1.Fixed-Duration Options for CLL

EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study

EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

EP: 4.Sequencing Considerations in Relapsed/Refractory CLL

EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors

EP: 8.Switching Between BTK Inhibitors in CLL

EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity

Now Viewing

EP: 10.Opportunities for Easing BTK Inhibitor Switches

EP: 11.Reflections on 2024’s Progress in R/R CLL

Video content above is prompted by the following:

• What challenges do you face when switching between BTK inhibitors, and what strategies can help mitigate these challenges?
• How can oncologists better educate patients about the potential for switching BTK inhibitors to manage toxicities without compromising treatment outcomes?

Related Videos

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.